chronic
obstruct
pulmonari
diseas
copd
fifth
common
caus
death
world
increas
mortal
rate
much
morbid
mortal
relat
episod
symptom
deterior
ie
acut
exacerb
ae
punctuat
cours
diseas
ae
copd
account
approxim
one
ten
emerg
medic
admiss
hospit
inhospit
mortal
ae
respons
direct
cost
attribut
copd
ae
gener
becom
frequent
sever
sever
underli
copd
progress
averag
patient
moder
sever
copd
typic
attend
secondari
care
one
two
ae
requir
addit
treatment
annual
howev
larg
differ
annual
ae
incid
rate
individu
patient
prone
frequent
ae
experi
particular
burden
diseas
outlin
figur
factor
predispos
patient
frequent
ae
poorli
understood
may
includ
daili
bronchit
symptom
greater
sever
underli
diseas
greater
airway
inflamm
stabl
state
predisposit
acquir
respiratori
viral
infect
andor
presenc
lower
airway
bacteri
colon
describ
later
pathophysiolog
copd
defin
world
health
organ
diseas
state
character
airflow
limit
progress
fulli
revers
associ
abnorm
inflammatori
respons
noxiou
particl
gase
airway
inflamm
even
greater
time
ae
assumpt
made
addit
inflamm
provok
symptom
worsen
dyspnea
sputum
product
mechan
relat
airway
tone
airway
wall
edema
mucu
product
result
airtrap
increas
work
breath
caus
addit
impair
respiratori
muscl
function
trigger
increas
airway
inflamm
therefor
consid
common
caus
ae
predominantli
tracheobronchi
infect
lesser
role
pollut
effect
increas
inflamm
ae
requir
clarif
howev
direct
relationship
clinic
sever
ae
degre
airway
inflamm
never
conclus
demonstr
defin
role
airway
infect
caus
ae
simpl
task
recent
advanc
molecular
biolog
enabl
isol
respiratori
virus
potenti
pathogen
bacteria
airway
mani
patient
exacerb
common
organ
identifi
list
tabl
patient
sever
underli
diseas
howev
also
colon
bacteria
stabl
state
presenc
organ
ae
therefor
impli
role
caus
exacerb
recent
suggest
chang
colon
bacteri
strain
may
precipit
event
howev
strain
chang
associ
ae
ae
associ
strain
chang
reflect
discuss
later
antibiot
may
univers
benefit
ae
rhinoviru
commonli
identifi
viral
pathogen
consequ
ae
common
winter
month
viral
circul
commun
higher
role
atyp
organ
chlamydia
mycoplasma
speci
remain
unclear
larg
epidemiolog
studi
link
increas
pollut
level
increas
hospit
admiss
respiratori
diseas
pm
particul
matter
less
mm
size
appear
particularli
import
possibl
pollut
microorgan
may
interact
amplifi
risk
exacerb
recent
recogn
copd
associ
system
inflamm
ampl
evid
demonstr
system
inflamm
increas
ae
may
import
given
associ
cardiovascular
death
rais
system
inflammatori
marker
find
mani
patient
copd
die
cardiovascular
diseas
system
inflamm
thought
repres
spill
lung
understand
pathophysiolog
ae
promot
appreci
rational
variou
therapi
use
bronchodil
may
help
increas
bronchoconstrict
hyperinfl
corticosteroid
may
reduc
airway
inflamm
antibiot
may
appropri
ae
caus
bacteria
although
make
distinct
difficult
concept
illustr
figur
variou
therapeut
strategi
describ
detail
follow
section
cardin
featur
ae
increas
respiratori
symptom
beyond
usual
patient
typic
symptom
includ
dyspnea
sputum
product
sputum
purul
cough
wheez
perhap
accompani
upper
respiratori
tract
symptom
rhinorrhea
peripher
edema
andor
confus
clinic
sign
nonspecif
may
includ
tachycardia
tachypnea
cyanosi
use
accessori
respiratori
muscl
polyphon
expiratori
wheez
crackl
auscult
abnorm
mental
statu
elev
jugular
venou
pressur
edema
manifest
cor
pulmonal
ae
heterogen
event
clinic
featur
vari
wide
patient
mild
underli
diseas
may
experi
troublesom
worsen
symptom
wherea
sever
copd
signific
risk
respiratori
failur
furthermor
condit
occur
patient
underli
copd
may
mimic
complic
exacerb
proper
assess
describ
therefor
import
ae
copd
clinic
syndrom
confirmatori
diagnost
test
although
controversi
exact
definit
ae
although
differ
may
import
interpret
result
variou
studi
wide
accept
ae
may
defin
sustain
worsen
patient
symptom
acut
onset
beyond
daytoday
variat
may
necessit
chang
therapi
although
laboratori
investig
help
diagnosi
ae
diagnost
test
valu
assess
sever
event
exclud
condit
may
mimic
complic
syndrom
diagnos
includ
pneumonia
pneumothorax
pulmonari
embolu
cardiac
failur
appropri
investig
would
therefor
includ
chest
radiograph
electrocardiogram
oxygen
satur
arteri
blood
ga
analysi
simpl
venou
blood
test
includ
full
blood
count
urea
electrolyt
creactiv
protein
spirometri
gener
help
absolut
valu
may
mislead
chang
exacerb
small
patient
acut
dyspneic
may
difficulti
perform
maneuv
accur
sputum
microscopi
cultur
may
help
refin
empir
antibiot
therapi
improv
resist
pseudomona
infect
role
microbiolog
studi
initi
evalu
clarifi
mild
exacerb
respond
increas
inhal
bronchodil
alon
investig
may
warrant
accept
method
assess
exacerb
sever
quantifi
chang
symptom
lung
function
gener
help
difficult
achiev
requir
knowledg
patient
baselin
consequ
degre
health
care
util
use
surrog
assess
sever
mild
exacerb
defin
requir
increas
inhal
bronchodil
moder
exacerb
requir
antibiot
corticosteroid
commun
sever
exacerb
requir
hospit
admiss
ph
best
indic
acut
chang
alveolar
ventil
exacerb
associ
respiratori
failur
requir
hospit
assess
decis
admit
patient
hospit
howev
depend
sever
exacerb
would
includ
exampl
patient
social
circumst
support
avail
patient
home
principl
therapi
time
ae
twofold
modifi
cours
event
support
respiratori
function
diseasemodifi
therapi
abl
act
treatment
given
proport
clinic
sever
event
sequenti
approach
illustr
figur
mani
publish
guidelin
exist
guid
appropri
therapi
includ
recent
evidencebas
statement
uk
nation
institut
clinic
evid
nice
attent
comorbid
also
import
recoveri
phase
one
consid
intervent
may
reduc
risk
subsequ
exacerb
increas
dose
frequenc
inhal
shortact
bronchodil
mainstay
therapi
littl
choos
term
bronchodil
effect
b
agonist
salbutamol
albuterol
anticholinerg
drug
ipratropium
bromid
although
often
use
combin
littl
evid
suggest
addit
benefit
also
evid
administ
medic
nebul
effect
metereddos
inhal
largevolum
spacer
howev
nebul
often
prefer
dyspneic
patient
nebul
copd
driven
compress
air
rather
oxygen
concern
effect
high
alveolar
oxygen
tension
ventilationperfus
relationship
patient
prescrib
longact
bronchodil
could
continu
therapi
littl
evid
support
introduc
longact
agent
ae
shortact
drug
prefer
recommend
approach
therefor
increas
dose
frequenc
either
shortact
b
agonist
anticholinerg
drug
use
togeth
event
inadequ
clinic
respons
system
corticosteroid
indic
mildest
exacerb
respond
increas
inhal
bronchodil
alon
number
random
trial
summar
systemat
review
demonstr
rapid
improv
fev
administr
steroid
although
effect
outcom
oxygen
hospit
length
hospit
stay
variabl
effect
mortal
document
guidelin
vari
specif
recommend
gener
suggest
oral
prednison
dose
mg
day
prolong
cours
addit
benefit
increas
risk
side
effect
evid
suggest
taper
dose
advantag
mani
physician
choos
give
first
dose
intraven
nebul
budesonid
result
similar
improv
lung
function
oral
dose
expens
intriguingli
use
system
steroid
may
delay
time
subsequ
exacerb
although
role
initi
inhal
steroid
exacerb
inhal
corticosteroid
also
import
role
exacerb
prevent
discuss
follow
semin
work
antibiot
exacerb
anthonisen
colleagu
demonstr
benefit
patient
increas
least
two
follow
three
symptom
breathless
sputum
volum
sputum
purul
sputum
purul
reliabl
indic
presenc
bacteria
exacerb
metaanalysi
six
suffici
welldesign
random
trial
saint
colleagu
confirm
small
statist
signific
benefit
favor
antibiot
local
resist
pattern
antibiot
polici
dictat
choic
drug
coverag
includ
common
pathogen
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
oral
aminopenicillin
macrolid
tetracyclin
therefor
appropri
empir
choic
compar
data
across
drug
class
spars
intraven
antibiot
rare
requir
littl
data
optim
durat
therapi
oxygen
indic
correct
hypoxem
respiratori
failur
may
occur
ae
hypoxemia
due
combin
increas
ventilationperfus
mismatch
alveolar
hypoventil
oxygen
administ
control
manner
monitor
arteri
blood
ga
tension
satur
avoid
co
retent
develop
hypercapn
respiratori
failur
may
occur
portion
patient
studi
shown
littl
risk
hypercapnia
oxygen
titrat
maximum
satur
failur
correct
hypoxemia
fio
suggest
presenc
addit
patholog
pulmonari
embolu
achiev
adequ
oxygen
expens
rise
paco
fall
ph
indic
ventilatori
support
venturi
mask
provid
reliabl
fio
nasal
cannula
latter
may
better
toler
noninvas
ventil
niv
refer
provis
ventilatori
support
mean
nasal
fullfac
mask
absenc
endotrach
tube
consider
evid
support
use
niv
patient
hypercapn
respiratori
failur
caus
ae
benefit
mortal
addit
reduct
hospit
stay
complic
cost
may
larg
attribut
reduc
need
sedat
intub
invas
ventil
addit
contrast
invas
ventil
niv
may
use
earlier
intermitt
therefor
facilit
commun
nutrit
physiotherapi
niv
usual
administ
pressurecycl
bilevel
posit
airway
pressur
inspiratori
expiratori
pressur
may
independ
vari
niv
howev
substitut
invas
ventil
latter
requir
therefor
plan
manag
made
regard
suitabl
invas
ventil
niv
fail
addit
patient
may
rel
contraind
niv
respiratori
failur
sever
immedi
assess
invas
ventil
indic
rel
contraind
niv
provid
tabl
patient
suitabl
niv
abl
toler
treatment
applic
nasal
mask
niv
exacerb
illustr
figur
primari
indic
invas
ventil
exacerb
copd
sever
hypoxia
respiratori
acidemia
ph
patient
unsuit
fail
niv
howev
although
data
suggest
patient
copd
similar
outcom
invas
ventil
seen
patient
respiratori
failur
caus
decis
institut
invas
ventil
consid
prior
function
statu
patient
sever
current
underli
ill
degre
revers
present
deterior
presenc
sever
comorbid
wish
patient
famili
caregiv
mortal
invas
ventil
approxim
wean
ventil
challeng
set
niv
may
valuabl
aim
ventil
support
ga
exchang
respiratori
muscl
function
therapi
suffici
time
effect
circumst
corticosteroid
antibiot
usual
given
parenter
bronchodil
drug
may
ad
ventil
circuit
inhal
spacer
methylxanthin
drug
theophyllin
varieti
potenti
benefici
effect
respiratori
cardiac
function
yet
random
control
trial
fail
show
benefit
lung
function
symptom
exacerb
despit
addit
wellrecogn
problem
drug
interact
side
effect
narrow
therapeut
rang
necessit
monitor
drug
level
theophyllin
still
sometim
use
patient
demonstr
suffici
progress
otherwis
maxim
therapi
one
action
theophyllin
phosphodiesteras
pde
inhibitor
newer
select
pde
inhibitor
current
tri
although
initi
result
disappoint
data
support
use
intraven
salbutamol
exacerb
copd
side
effect
common
inhal
rout
routin
use
recommend
although
exacerb
often
associ
increas
volum
tenac
sputum
current
firm
evid
support
use
mucolyt
drug
treat
ae
copd
also
evid
support
strategi
aim
facilit
expector
physiotherapi
salin
nebul
although
larg
reflect
absenc
evid
rather
evid
support
absenc
benefit
cough
suppress
contraind
central
respiratori
stimul
intraven
doxapram
supersed
avail
niv
therapi
clearli
superior
manag
hypercapn
respiratori
failur
limit
role
doxapram
may
remain
niv
appropri
bridg
niv
specialist
advic
conjunct
niv
use
doxapram
often
limit
side
effect
especi
agit
potenti
benefit
appear
persist
beyond
h
although
intraven
magnesium
may
effect
bronchodil
exacerb
asthma
convinc
data
support
effect
ae
copd
routin
use
recommend
heliox
mixtur
helium
oxygen
lower
viscos
air
may
therefor
reduc
work
breath
howev
remain
evid
benefit
treat
ae
copd
support
measur
institut
includ
appropri
attent
fluid
balanc
consider
prophylaxi
venou
thromboembol
final
patient
respond
maxim
therapi
escal
inappropri
rang
palli
approach
achiev
symptom
control
consid
use
analysi
symptom
lung
function
chang
median
length
exacerb
approxim
day
although
wide
variabl
proport
exacerb
take
consider
longer
improv
patient
appear
never
fulli
recov
preexacerb
lung
function
patient
admit
hospit
inhospit
mortal
approxim
patient
hypercapn
respiratori
failur
mortal
approach
year
patient
may
suitabl
earli
support
discharg
scheme
although
associ
similar
outcom
appear
costeffect
standard
care
given
import
ae
manag
acut
event
import
consid
institut
rang
prevent
measur
reduc
risk
futur
ae
accumul
evid
suggest
number
class
medic
reduc
incid
ae
includ
longact
b
agonist
longact
anticholinerg
inhal
corticosteroid
least
moder
sever
underli
diseas
combin
therapi
longact
b
agonist
inhal
corticosteroid
appear
superior
use
either
compon
alon
combin
may
also
mortal
benefit
oral
corticosteroid
ineffect
prevent
exacerb
also
effect
outcom
measur
indic
stabl
copd
ongo
trial
reexamin
role
antibiot
reduc
exacerb
frequenc
exist
evid
drug
may
effect
mani
exist
trial
includ
patient
simpl
chronic
bronchiti
drug
use
older
benefit
must
balanc
possibl
promot
drug
resist
macrolid
hold
particular
promis
given
recogn
antiinflammatori
action
vaccin
influenza
pneumonia
recommend
pulmonari
rehabilit
also
shown
reduc
hospit
patient
copd
furthermor
earli
treatment
shown
reduc
exacerb
length
might
includ
patient
educ
program
therefor
varieti
measur
may
institut
reduc
number
consequ
exacerb
reason
assess
patient
present
respiratori
failur
usual
appropri
review
patient
ambulatori
care
set
admiss
acut
exacerb
recent
increas
research
focus
ae
copd
still
understand
littl
relationship
ae
bacteri
type
load
bacteri
viral
pathogen
might
interact
effect
antiinflammatori
agent
requir
role
antibiot
prevent
exacerb
unclear
current
effect
intervent
target
viral
pathogen
especi
rhinoviru
final
recogn
copd
associ
system
inflamm
may
caus
consider
cardiovascular
comorbid
way
assess
manag
may
also
lead
reduct
number
impact
exacerb
